Industry Spotlight  |
Therapeutic Modalities

Immunostimulatory Oncolytic Viruses: Interview with Angelica Loskog, CEO, Lokon Pharma

Edited by Tom Cohen |
14 November 2023
Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.

We had the privilege of sitting down with Angelica Loskog, Professor of Immunotherapy at Uppsala University in Sweden and the CEO of Lokon Pharma, a cutting-edge immunotherapy company making strides in the field. As a leader in the realm of oncolytic viruses and immunostimulatory gene therapy, Professor Loskog shared valuable insights into Lokon Pharma’s groundbreaking work.


Want to read more about new advances in immuno-oncology and ongoing immune therapies? Sign up to our Immuno newsletter to receive leading experts opinions, research and cutting-edge presentations on the latest advancements in cancer immunotherapy, with dedicated sessions on different therapeutic modalities as well as case studies on innovative preclinical and translational tools.

Speaker Biographies

Angelica has over 20 years immune oncology experience (Uppsala University and Baylor College of Medicine). She has a PhD in Medical Sciences from Uppsala University and is currently adjunct as a Professor of immunotherapy. She is an advisor to NEXTTOBE and is a board member of several of their portfolio companies.

How would you rate this content?

Share this article

Sign up for our monthly Immuno Newsletter

You may also be interested in...

Industry Spotlight
Talking with Laura von Schantz, Chief Technology Officer, at Alligator Biosciences about their RUBY bispecific antibody format.
02 November 2023
A proteomics platform driving pioneering discoveries
27 October 2023

Continue browsing

Share this article

Join our Immuno mailing list

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Immuno